F. Cantero

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Jordi Bertrán-Alamillo, Valérie Cattan, Marie Schoumacher et al. · Nature Communications · 2019 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +17

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours

Patrick Schöffski, Ahmad Awada, Anne-Marie De La Bigne et al. · European Journal of Cancer · 2022 · 33 citations · Full text

Medicine, Oncology, Pharmacology +16

HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic <i>EGFR</i> -mutated NSCLC

Helena A. Yu, James Chih‐Hsin Yang, Hidetoshi Hayashi et al. · Future Oncology · 2023 · 26 citations · Full text

Medicine, Oncology, Pharmacology +15

47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01

Michele Droz Dit Busset, Walid L. Shaib, Kabir Mody et al. · Annals of Oncology · 2021 · 20 citations · Full text

Medicine, Oncology, Pharmacology +16

FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.

Arvind Chaudhry, Cora N. Sternberg, Maria De Santis et al. · Journal of Clinical Oncology · 2020 · 12 citations

Medicine, Oncology, Pharmacology +17